Do These 2 Numbers From Pfizer Spell Trouble for Moderna?
Pfizer (NYSE: PFE) stepped ahead of Moderna (NASDAQ: MRNA) nearly a year ago when it won the first authorization for a coronavirus vaccine. Of course, Moderna's vaccine entered the market a couple of weeks later. And together, the two companies vaccinated most Americans.
It's fair to call them both market leaders. That said, Pfizer has steadily vaccinated more individuals that Moderna. And two numbers from Pfizer show this isn't about to change. In fact, the gap is widening. The big pharmaceutical company says its U.S. market share has grown to 74% from 56% back in April. And its European market share has climbed to 80% from 70%. This refers to vaccines administered. Now the question is: Do these two numbers mean trouble ahead for Moderna?
Image source: Getty Images.
Source Fool.com
